FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	OMB APPROVAL						
OMB Number: 3235-03							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	

Instruc	tion 1(b).							a) of the Secu Investment (934		[Hodis p			0.0
Name and Address of Reporting Person* Benatti Luca					2. Issuer Name and Ticker or Trading Symbol Quince Therapeutics, Inc. [QNCX] Solution Symbol (Check all applicable) X Director 10% Owner											
(Last)	(F	rst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 10/23/2023							Officer below)	Ot	Other (specify below)		
C/O QUINCE THERAPEUTICS, INC. 601 GATEWAY BLVD, SUITE 1250				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street)	SAN C	Δ	94080									Form f Persor	iled by More	than One I	Report	ting
FRANCI	isco C.	Rule 10b5-1(c) Transaction Indication								.						
(City)	(City) (State) (Zip) Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									to						
		Tab	le I - Non-De	rivativ	e Se	curities	S Ac	quired, D	isposed o	of, or Be	neficial	y Owned				
Date			ansactior e nth/Day/Y	Execution Date,		Code (Instr. 5)				Beneficia Owned F	s Formally (D) of ollowing (I) (I	6. Ownershi Form: Direc (D) or Indire (I) (Instr. 4)	t o	7. Nature of Indirect Beneficial Ownership		
							Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			Instr. 4)	
		-	Table II - Deri (e.g	vative ., puts,	Secu calls	urities . s, warr	Acq ants	uired, Dis s, options	posed of converti	, or Bene ble secu	eficially irities)	Owned				
Derivative Conversion or Exercise (Month/Day/Year) Execution Date, If any		Code (ansaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owne Form Direct or Ind (I) (In:	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (right to buy)	\$0.99	10/23/2023		A		54,000		(1)	10/22/2033	Common Stock	54,000	\$0.00	54,000	I		

Explanation of Responses:

1. The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of October 23, 2023, subject to the Reporting Person's continued service as a member of the Board of Directors of the Issuer as of each such vesting date.

Remarks:

/s/ Brendan Hannah, Attorney-

10/24/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.